MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DG INNOVATE PLC Logo
Develops sustainable tech for EV drivetrains and next-gen energy storage materials.
United Kingdom
DGI
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America
DNTH
Dogwood Therapeutics, Inc. Logo
Developing non-opioid therapeutics for neuropathic pain, fibromyalgia, and cancer-related pain.
United States of America
DWTX
DreamCIS INC. Logo
A CRO providing clinical research services for pharma, biotech, and medical device industries.
South Korea
223250
DT&CRO CO., Ltd. Logo
A full-service CRO for pharma & biotech, from non-clinical studies to FDA approval support.
South Korea
383930
D.Western Therapeutics Institute, Inc. Logo
Biotech firm discovering and licensing drug candidates, focusing on kinase inhibitors.
Japan
4576
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden
ECTIN B
EdgeLab S.p.A. Logo
Specializing in underwater robotics, AUVs, and sensor systems for marine research and heritage.
Italy
ELB
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America
EDIT
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America
ELDN

Talk to a Data Expert

Have a question? We'll get back to you promptly.